BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 21615994)

  • 61. Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL.
    Jabłońska J; Jesionek-Kupnicka D; Potemski P; Kowalik A; Sygut J; Kordek R
    Pol J Pathol; 2010; 61(3):124-32. PubMed ID: 21225494
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.
    Lu TX; Miao Y; Wu JZ; Gong QX; Liang JH; Wang Z; Wang L; Fan L; Hua D; Chen YY; Xu W; Zhang ZH; Li JY
    Sci Rep; 2016 Feb; 6():20465. PubMed ID: 26857366
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.
    Gu K; Weisenburger DD; Fu K; Chan WC; Greiner TC; Aoun P; Smith LM; Bast M; Liu Z; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Hematol Oncol; 2012 Sep; 30(3):143-9. PubMed ID: 22009820
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia.
    Peh SC; Gan GG; Lee LK; Eow GI
    Pathol Int; 2008 Sep; 58(9):572-9. PubMed ID: 18801072
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
    Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
    Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biological characterization of nodal versus extranodal presentation of diffuse large B-Cell lymphoma using immunohistochemistry.
    Kim MK; Bae SH; Bae YK; Kum YS; Ryoo HM; Cho HS; Lee KH; Koh SA; Lee HY; Yun SY; Choi JH; Hyun MS
    Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):403-8. PubMed ID: 21700526
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland.
    Reber R; Banz Y; Garamvölgyi E; Perren A; Novak U
    Swiss Med Wkly; 2013; 143():w13748. PubMed ID: 23740154
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
    Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
    Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
    Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
    Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients].
    Chen CQ; Yin L; Peng CH; Ye M; Zhao R; Chen GM; Zhou HJ; Li HW; Fan YZ
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):693-6. PubMed ID: 18246801
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Clinicopathologic features and expression of OCT4 protein in testicular diffuse large B cell lymphoma].
    Chen YP; Zhu WF; Chen LF; Lu JP; He TM; Fu WD; Xu CW; Chen G
    Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):383-387. PubMed ID: 28591984
    [No Abstract]   [Full Text] [Related]  

  • 75. The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas.
    Rayman N; Lam KH; van der Holt B; Koss C; van Leeuwen J; Budel LM; Mulder AH; Sonneveld P; Delwel R
    Eur J Haematol; 2011 Jun; 86(6):466-76. PubMed ID: 21457344
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
    Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
    Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
    Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
    Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.